肿瘤免疫治疗超进展的研究和展望  

Research progress and prospect of tumor immunotherapy

作　　者：杨宏 李皓静 罗丹阳 何敏 陈速研 王相成[2] 杨昊 YANG Hong;LI Haojing;LUO Danyang;HE Min;CHEN Suyan;WANG Xiangcheng;YANG Hao(Department of Oncology,Inner Mongolia People's Hospital,Hohhot,Inner Mongolia 010017,China;Affiliated Hos-pital of Inner Mongolia Medical University,Hohhot,Inner Mongolia 010050,China;Tumor Hospital of Inner Mongolia Autonomous Region,Hohhot,Inner Mongolia 010020,China)

机构地区：[1]内蒙古自治区人民医院肿瘤内科,内蒙古自治区呼和浩特市010017 [2]内蒙古医科大学附属医院,内蒙古自治区呼和浩特市010050 [3]内蒙古自治区肿瘤医院,内蒙古自治区呼和浩特市010020

出　　处：《中南医学科学杂志》2022年第2期297-301,共5页Medical Science Journal of Central South China

基　　金：国家自然科学基金(81860534);北京医学奖励基金会(YXJL-20200785-0315);第二届三生TCP中青年科研基金(8);内蒙古自治区科技计划项目(2019GG086,2019GG039,2021GG0167)。

摘　　要：近年来,免疫治疗成为肿瘤治疗的热点并在多个瘤种中广泛应用。然而免疫治疗为肿瘤患者带来益处的同时,有时会出现肿瘤生长速度加快或者肿瘤负荷快速增大并产生新病灶的情况,临床上将其称为“超进展(HPD)”。目前关于HPD的争议很多,包括HPD的定义和评估标准,以及生物标志物和发生机制等相关问题未完全明确。因此,本文对目前国内外关于HPD的定义及评估标准、高危因素预测、鉴别等进行系统综述,以期对未来HPD的研究及今后临床实践优化提供帮助。In recent years, tumor immunotherapy has become a hot spot in tumor therapy and has been widely used in many tumor species. However, while immunotherapy has brought significant benefits to tumor patients, a number of clinical trials have shown that sometimes after immunotherapy, tumor growth rate or tumor load increases rapidly and new lesions are generated, which is clinically referred to as “hyperprogressive disease(HPD)”. At present, there are many controversies about HPD, including the definition and evaluation criteria of HPD, as well as the related issues such as biomarkers and occurrence mechanism, which are not completely clear. Therefore, this paper systematically reviewed the definition, assessment criteria, risk factor prediction and identification of HPD at home and abroad, with a view to providing help for future research on HPD and optimization of clinical practice in the future.

关 键 词：肿瘤 免疫检查点抑制剂 超进展 鉴别 预测指标 

分 类 号：R730.3[医药卫生—肿瘤]